Announced today that all patients enrolled in its Phase II/III psoriasis trial for the Firm&39.

Can-Fite enrolled 326 patients through 17 scientific centers in the U.S., Europe, and Israel. The first study cohort was comprised of three hands with patients receiving: 1 mg of CF101; 2 mg of CF101; and placebo. All sufferers receiving placebo were switched to either 1 mg or 2 mg of CF101 after 12 weeks. The principal efficacy endpoints certainly are a statistically significant improvement in regular measures utilized by dermatologists to assess psoriasis like the Psoriasis Area Sensitivity Index rating and the secondary end points among others will be the Doctors' Global Assessment score as well as various safety parameters.. Can-Fite BioPharma completes affected individual enrollment in CF101 Phase II/III psoriasis trial Can-Fite BioPharma Ltd. , a biotechnology company with a pipeline of proprietary small molecule medications that address cancers and inflammatory diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Firm's drug applicant CF101 have completed the research's 32 week treatment process. Continue reading

Are You a Diabetic?

The distance of the recovery period varies, according to the kind of nerve damage. * Lastly, focal neuropathy affects eyes, ears, pelvis, hip and legs, etc. It causes the shortcoming to focus the optical eye, double vision, aching behind one attention, paralysis using one side of the facial skin, called Bells Palsy, serious pain in the lower back or pelvis, pain in leading of a thigh, discomfort in the chest, stomach, or side, pain on the outside of the shin or within the foot, chest or abdominal pain that is sometimes mistaken for cardiovascular disease, a heart attack, or appendicitis. Every single one of the neuropathies are serious and may be devastating! You should do everything in your capacity to do what it takes to avoid the progression of the disease in your body. Continue reading

Fresh Danish research suggests.

Regarding to his personal statistical breakdown, Myers stated that between 2000 and 2011, glioma affected significantly less than two from every 100,000 American women between your age range of 15 and 29. To place that in perspective, he stated, that’s about one-tenth the chance of loss of life from trauma in ladies aged 15 to 44, and just a little over twice the chance of dying from a complication of pregnancy. Myers stated his number-crunching suggests a straight lower risk profile when searching specifically at females who are acquiring the Tablet or another type of hormonal contraception. Continue reading